Global Peripheral Drug-eluting Balloon Market Strategic Research Report

Scope of the Report

The global Peripheral Drug-eluting Balloon market size is predicted to grow from US$ 793 million in 2025 to US$ 1,777 million in 2032; it is expected to grow at a CAGR of 12.2% from 2026 to 2032.

Peripheral drug-eluting balloons (often referred to as peripheral drug-coated balloons, DCBs) are endovascular angioplasty balloons designed for peripheral arteries (commonly femoropopliteal segments), coated with an antiproliferative drug (typically paclitaxel or “limus” agents) plus an excipient/carrier system. During inflation, they provide immediate lumen gain while rapidly transferring drug into the vessel wall to suppress neointimal hyperplasia and reduce restenosis and repeat interventions. The strategic concept is “leave nothing behind,” aiming to avoid the long-term burden of permanent implants and preserve flexibility for future revascularization, increasingly combined with lesion preparation and intravascular imaging to enable more repeatable peripheral vascular repair pathways.In 2025, global Peripheral drug-eluting balloons production reached approximately 773 k units and price is 1048 USD/Unit.The average gross profit margin of this product is 73%.

Opportunities are anchored in the long-term shift toward minimally invasive, repair-centric peripheral interventions. A clearer safety boundary has strengthened adoption confidence: the U.S. FDA’s updated communication on paclitaxel-coated devices for PAD states that the totality of available evidence does not support an increased mortality risk, enabling more actionable hospital governance and pathway standardization. In parallel, leading companies explicitly position peripheral drug-coated balloons within their core peripheral intervention portfolios in annual reporting, signaling a transition from selective use to routine toolset adoption with ongoing room for technology iteration and category expansion.

The competitive bar is shifting from “availability” to “scalable reproducibility and compliant delivery.” As drug–device combination products, peripheral DCBs are highly sensitive to coating integrity, particulate control, dose consistency, and shelf-life stability—where process drift can translate into outsized clinical reputation and access risk. Meanwhile, cost-containment and procurement reforms intensify the need to balance quality systems, supply assurance, and cost efficiency. In China, the National Healthcare Security Administration published the winning results for the national procurement of drug-coated balloons on January 14, 2026, accelerating a more rules-based, scale-driven market phase.

Demand is consolidating around repeatable techniques and bundled solutions. High recurrence and reintervention sensitivity in peripheral disease elevate the importance of integrated optimization—lesion preparation, drug-transfer efficiency, and durable patency—driving more routine combination of DCBs with plaque-modification tools, specialty scoring balloons, and intravascular imaging (IVUS/OCT). Procurement implementation further encourages hospitals to formalize compliant pathways and device bundles, shifting growth from “operator preference–driven” to “pathway management–driven” adoption.

Upstream differentiation is ultimately an integrated “materials–coating–validation” capability. Key inputs include balloon/catheter polymers and reinforcements, drug APIs (paclitaxel or limus agents) with excipient/carrier systems, coating solvents and metrology consumables, lubricious/hydrophilic surface coatings, plus sterile barrier packaging and sterilization services. With procurement pressure and global compliance expectations in parallel, suppliers are increasingly evaluated on medical-grade traceability, clean manufacturing, and change control. The ability to industrialize coating consistency, yield, and batch-release stability as a platform capability directly determines scalable delivery efficiency and brand credibility.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Peripheral Drug-eluting Balloon market?

What factors are driving Peripheral Drug-eluting Balloon market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Peripheral Drug-eluting Balloon market opportunities vary by end market size?

How does Peripheral Drug-eluting Balloon break out by Type, by Application?

This report presents a comprehensive overview of the global Peripheral Drug-eluting Balloon market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Paclitaxel
• Others

Segment by Balloon Platform Mechanics

• Semi-/Compliant
• Non-compliant
• Other

Segment by Application

• Lower Limbs
• Renal Artery
• Carotid Artery

Segment by Application

• In-Stent Restenosi
• De Novo
• Small Vessel

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Peripheral Drug-eluting Balloon market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in In-Stent Restenosi, De Novo, Small Vessel evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact